CAMBRIDGE, Mass., April 14, 2026 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company today announced the expansion of its ...
Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks while running entirely on private pharmaceutical infrastructure CAMBRIDGE, Mass., March 3, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results